vs
Side-by-side financial comparison of DENNY'S Corp (DENN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $113.2M, roughly 1.6× DENNY'S Corp). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 0.6%, a 1.1% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -0.9%).
Denny's is an American table service diner-style restaurant chain. It operates over 1,400 restaurants in the United States, Canada, México, Puerto Rico, and several other international locations.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DENN vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $113.2M | $177.4M |
| Net Profit | $632.0K | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 9.2% | 3.9% |
| Net Margin | 0.6% | 1.6% |
| Revenue YoY | 1.3% | 5.0% |
| Net Profit YoY | -90.3% | — |
| EPS (diluted) | $0.01 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $113.2M | $179.5M | ||
| Q2 25 | $117.7M | $181.1M | ||
| Q1 25 | $111.6M | $168.9M | ||
| Q4 24 | $114.7M | $187.3M | ||
| Q3 24 | $111.8M | $168.6M | ||
| Q2 24 | $115.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $632.0K | $5.4M | ||
| Q2 25 | $2.5M | $-4.8M | ||
| Q1 25 | $326.0K | $4.8M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $6.5M | $-143.5M | ||
| Q2 24 | $3.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 9.2% | 3.5% | ||
| Q2 25 | 7.3% | 4.7% | ||
| Q1 25 | 4.7% | 1.2% | ||
| Q4 24 | 12.6% | 13.2% | ||
| Q3 24 | 10.5% | -82.8% | ||
| Q2 24 | 7.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.6% | 3.0% | ||
| Q2 25 | 2.1% | -2.7% | ||
| Q1 25 | 0.3% | 2.8% | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 5.8% | -85.1% | ||
| Q2 24 | 3.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.01 | $0.12 | ||
| Q2 25 | $0.05 | $-0.11 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $0.13 | $0.38 | ||
| Q3 24 | $0.12 | $-3.11 | ||
| Q2 24 | $0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-32.7M | $653.9M |
| Total Assets | $502.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | $1.1M | $493.6M | ||
| Q4 24 | $100.0K | $484.6M | ||
| Q3 24 | $2.9M | $453.8M | ||
| Q2 24 | $2.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $270.6M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | $-32.7M | $727.2M | ||
| Q2 25 | $-34.6M | $757.8M | ||
| Q1 25 | $-36.4M | $798.5M | ||
| Q4 24 | $-34.0M | $778.3M | ||
| Q3 24 | $-54.5M | $749.6M | ||
| Q2 24 | $-53.2M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $502.9M | $1.3B | ||
| Q2 25 | $491.1M | $1.5B | ||
| Q1 25 | $488.1M | $1.6B | ||
| Q4 24 | $496.3M | $1.6B | ||
| Q3 24 | $461.6M | $1.5B | ||
| Q2 24 | $459.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.0M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 14.1% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 25.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | $16.0M | $60.8M | ||
| Q2 25 | $9.4M | $12.0M | ||
| Q1 25 | $5.0M | $35.5M | ||
| Q4 24 | $8.5M | $33.1M | ||
| Q3 24 | $6.6M | $53.9M | ||
| Q2 24 | $14.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | $16.0M | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | 14.1% | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25.28× | 11.20× | ||
| Q2 25 | 3.79× | — | ||
| Q1 25 | 15.38× | 7.37× | ||
| Q4 24 | 1.26× | — | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 3.97× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DENN
| Franchisor Owned Outlet | $57.4M | 51% |
| Royalty | $27.7M | 25% |
| Advertising | $18.6M | 16% |
| Occupancy | $7.7M | 7% |
| Initial And Other Fees | $1.7M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
